50,000 Shares in Tenax Therapeutics, Inc. (NASDAQ:TENX) Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics, Inc. (NASDAQ:TENX) during the third quarter, HoldingsChannel.com reports. The firm purchased 50,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $173,000.

Tenax Therapeutics Trading Up 0.6 %

Shares of TENX traded up $0.03 during midday trading on Wednesday, reaching $5.20. 11,749 shares of the company were exchanged, compared to its average volume of 255,105. Tenax Therapeutics, Inc. has a 1-year low of $2.77 and a 1-year high of $31.20. The stock has a 50-day moving average price of $4.13 and a 200-day moving average price of $3.74.

Analysts Set New Price Targets

TENX has been the subject of a number of research analyst reports. StockNews.com assumed coverage on Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating for the company. Leerink Partners started coverage on Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price objective on the stock. Guggenheim began coverage on Tenax Therapeutics in a research note on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Finally, William Blair started coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.